The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease

被引:3
|
作者
Hu, Yingying [1 ,2 ]
Zhou, Fan [3 ,4 ]
Lei, Fang [2 ,5 ]
Lin, Lijin [1 ,2 ]
Huang, Xuewei [6 ]
Sun, Tao [1 ,2 ]
Liu, Weifang [1 ,2 ]
Zhang, Xingyuan [2 ,5 ]
Cai, Jingjing [2 ,6 ]
She, Zhi-Gang [1 ,2 ]
Li, Hongliang [1 ,2 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan, Peoples R China
[2] Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China
[3] Yangtze Univ, Huanggang Cent Hosp, Dept Gastroenterol, Huanggang, Peoples R China
[4] Huanggang Inst Translat Med, Huanggang, Peoples R China
[5] Wuhan Univ, Sch Basic Med Sci, Wuhan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Cardiol, Changsha, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
基金
美国国家科学基金会;
关键词
metabolic dysfunction-associated fatty liver disease; thyroid function parameters; nonlinear relationship; restricted cubic spline analysis; multivariable-adjusted logistic regression models; STIMULATES LEPTIN SECRETION; FREE TRIIODOTHYRONINE; ADIPOSE-TISSUE; HORMONE; RISK; NAFLD; HYPOTHYROIDISM; PATHOGENESIS; THYROTROPIN; PREVALENCE;
D O I
10.3389/fendo.2023.1115354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease (MAFLD) remains controversial. Additionally, little is known about the relationship between thyroid function parameters and MAFLD in the Chinese population. MethodsWe conducted a retrospective cross-sectional study involving 177,540 individuals with thyroid function tests and MAFLD diagnosis from 2010-2018. The association between thyroid function parameters and MAFLD was evaluated on a continuous scale with restricted cubic spline (RCS) models and by the prior-defined centile categories with multivariable-adjusted logistic regression models. Thyroid function parameters included free triiodothyronine (FT3), free tetra-iodothyronine (FT4), and thyroid stimulating hormone (TSH). Additionally, fully adjusted RCS models stratified by sex, age, and location were studied. ResultsIn the RCS models, the risk of MAFLD increased with higher levels of FT3 when FT3 <5.58pmol/L, while the risk of MAFLD decreased with higher levels of FT3 when FT3 >= 5.58pmol/L (P nonlinearity <0.05). While RCS analysis suggested that the FT4 levels had a negative association with MAFLD (P nonlinearity <0.05), indicating an increase in FT4 levels was associated with a decreased risk of MAFLD. RCS analysis suggested an overall positive association between the concentration of TSH and MAFLD risk (P nonlinearity <0.05). The rising slope was sharper when the TSH concentration was less than 1.79uIU/mL, which indicated the association between TSH and MAFLD risk was tightly interrelated within this range. The multivariable logistic regression showed that populations in the 81st-95th centile had the highest risk of MAFLD among all centiles of FT3/TSH, with the 1st-5th centile as the reference category. ConclusionsOur study suggested nonlinear relationships between thyroid function parameters and MAFLD. Thyroid function parameters could be additional modifiable risk factors apart from the proven risk factors to steer new avenues regarding MAFLD prevention and treatment.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [22] Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease
    Perdomo, Carolina M.
    Nunez-Cordoba, Jorge M.
    Ezponda, Ana
    Mendoza, Francisco J.
    Ampuero, Javier
    Bastarrika, Gorka
    Fruhbeck, Gema
    Escalada, Javier
    FRONTIERS IN MEDICINE, 2022, 9
  • [23] Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
    Fouad, Yasser
    Alboraie, Mohamed
    Shiha, Gamal
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 827 - 833
  • [24] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Wang, Ting-Yao
    Wang, Rui-Fang
    Bu, Zhi-Ying
    Targher, Giovanni
    Byrne, Christopher D.
    Sun, Dan-Qin
    Zheng, Ming-Hua
    NATURE REVIEWS NEPHROLOGY, 2022, 18 (04) : 259 - 268
  • [25] Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones
    Zhang, Fan
    Li, Wenjian
    KIDNEY & BLOOD PRESSURE RESEARCH, 2025, 50 (01): : 115 - 130
  • [26] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [27] Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
    Barchetta, Ilaria
    Cimini, Flavia Agata
    Cavallo, Maria Gisella
    NUTRIENTS, 2020, 12 (11) : 1 - 14
  • [28] Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality
    Semmler, Georg
    Wernly, Sarah
    Bachmayer, Sebastian
    Leitner, Isabella
    Wernly, Bernhard
    Egger, Matthias
    Schwenoha, Lena
    Datz, Leonora
    Balcar, Lorenz
    Semmler, Marie
    Stickel, Felix
    Niederseer, David
    Aigner, Elmar
    Datz, Christian
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : 2670 - 2677
  • [29] Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis
    Kim, Donghee
    Dennis, Brittany B.
    Cholankeril, George
    Ahmed, Aijaz
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 329 : 184 - 191
  • [30] The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Kashihara, Takanori
    Shinomiya, Ryo
    Miyake, Takanori
    Kawaguchi, Tomoyuki
    Yokoyama, Reiko
    Kagemoto, Kaizo
    Kida, Yoshifumi
    Okada, Yasuyuki
    Tomonari, Tetsu
    Kawano, Yutaka
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1587 - 1598